Compare Pfizer with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs LUPIN - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER LUPIN PFIZER/
LUPIN
 
P/E (TTM) x 35.9 106.7 33.7% View Chart
P/BV x 6.1 2.4 250.4% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 PFIZER   LUPIN
EQUITY SHARE DATA
    PFIZER
Mar-19
LUPIN
Mar-19
PFIZER/
LUPIN
5-Yr Chart
Click to enlarge
High Rs3,840986 389.5%   
Low Rs2,080720 288.7%   
Sales per share (Unadj.) Rs455.0369.5 123.1%  
Earnings per share (Unadj.) Rs93.813.4 699.6%  
Cash flow per share (Unadj.) Rs109.437.4 292.6%  
Dividends per share (Unadj.) Rs22.500-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs658.2303.7 216.7%  
Shares outstanding (eoy) m45.75452.49 10.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.52.3 281.7%   
Avg P/E ratio x31.663.6 49.6%  
P/CF ratio (eoy) x27.122.8 118.6%  
Price / Book Value ratio x4.52.8 160.1%  
Dividend payout %24.00-   
Avg Mkt Cap Rs m135,420386,064 35.1%   
No. of employees `0002.617.7 14.9%   
Total wages/salary Rs m3,23831,513 10.3%   
Avg. sales/employee Rs Th7,911.49,453.8 83.7%   
Avg. wages/employee Rs Th1,230.91,782.0 69.1%   
Avg. net profit/employee Rs Th1,630.7343.0 475.4%   
INCOME DATA
Net Sales Rs m20,815167,182 12.5%  
Other income Rs m1,6743,640 46.0%   
Total revenues Rs m22,489170,822 13.2%   
Gross profit Rs m5,71228,822 19.8%  
Depreciation Rs m71410,850 6.6%   
Interest Rs m733,078 2.4%   
Profit before tax Rs m6,59918,534 35.6%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m2,3099,017 25.6%   
Profit after tax Rs m4,2916,066 70.7%  
Gross profit margin %27.417.2 159.2%  
Effective tax rate %35.048.7 71.9%   
Net profit margin %20.63.6 568.1%  
BALANCE SHEET DATA
Current assets Rs m27,167138,536 19.6%   
Current liabilities Rs m8,91761,299 14.5%   
Net working cap to sales %87.746.2 189.8%  
Current ratio x3.02.3 134.8%  
Inventory Days Days6884 80.9%  
Debtors Days Days30112 26.8%  
Net fixed assets Rs m8,862127,516 6.9%   
Share capital Rs m458905 50.6%   
"Free" reserves Rs m29,656136,517 21.7%   
Net worth Rs m30,113137,422 21.9%   
Long term debt Rs m2566,417 0.0%   
Total assets Rs m39,400279,494 14.1%  
Interest coverage x91.57.0 1,303.6%   
Debt to equity ratio x00.5 0.2%  
Sales to assets ratio x0.50.6 88.3%   
Return on assets %11.13.3 338.5%  
Return on equity %14.24.4 322.8%  
Return on capital %22.18.9 248.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42859,414 0.7%   
Fx outflow Rs m78622,282 3.5%   
Net fx Rs m-35837,132 -1.0%   
CASH FLOW
From Operations Rs m97816,660 5.9%  
From Investments Rs m351-32,825 -1.1%  
From Financial Activity Rs m-1,0997,441 -14.8%  
Net Cashflow Rs m231-8,724 -2.6%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 63.9 0.2 31,950.0%  
Indian inst/Mut Fund % 7.5 11.3 66.4%  
FIIs % 4.9 31.9 15.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 10.1 234.7%  
Shareholders   85,207 98,259 86.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   DISHMAN PHARMA  CADILA HEALTHCARE  SUVEN LIFESCIENCES  FDC LTD.  AUROBINDO PHARMA  

Compare PFIZER With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Nov 11, 2019 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS